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The incidence and mortality of gastric cancer have decreased significantly over the last two to three decades. However, gastric cancer is still one of the most common malignancies in the world. In Asian countries, such as China, Japan, Korea and other developing countries, the incidence and mortality of gastric cancer are the highest among all malignant tumors [1, 2] . At present, it is widely acknowledged that tumorigenesis of gastric cancer is a longterm process involved multigene and multistep. P21activated kinase 1 (PAK1), locates at 11q13.5q14, is a potential oncogene and an important downstream target protein of Cdc42 and Racl要members of RhoGTPase family [3, 4] . Recent studies have shown that PAK1 is highly expressed in many cancers and closely related to invasion and metastasis [5] . So far, it has been found that the PAK1 signaling pathway is activated in the tumorigenesis and development of gastric cancer and the downregulation of PAK1 expression could inhibit the growth of gastric cancer cells [6] . In this study, the expression of PAK1 in 189 specimens of gastric cancer, 54 specimens of adjacent tissues, 30 specimens of normal tissues and 40 specimens of corresponding lymph nodes was detected and its relationship with clinicopathological characteristics and survival of patients with gastric carcinoma was analyzed.
Wellpreserved paraffinembedded specimens of gastric cancer resected between 1999 and 2004 were obtained from Department of Pathology, Wuwei Tumor Hospital, including 189 specimens of gastric cancer, 40 specimens of corresponding metastatic lymph nodes, and 54 specimens of adjacent tissues (over 6 cm from cancer margin and without cancer cells confirmed by HE staining). All patients were confirmed by postoperative pathology and had complete clinical data. No patients received radiotherapy and chemotherapy. The patients who died within 4 weeks after surgery were excluded. Thirty specimens of negative cutside tissues (normal mucosa) were selected as controls. Of the 189 patients, 145 were men and 44 were women of 3073 years old, with a median age of 55 years. According to the WHO classification, 100 cases were poorly differentiated, 89 were highly or moderately differentiated; 7 cases at stage T1 (confined to mucosa), 39 at T2 (invading muscle), 86 at T3 (invading serosa layer), and 57 at T4 (invading adjacent organs); 116 cases with lymph node metastasis and 73 without. According to the Lauren classification, 97 cases were intestinal type, 85 were diffuse type, and 7 were mixed type. Tumor diameter was 逸 5 cm in 119 cases and < 5 cm in 70 cases. A total of 101 patients were followedup for 279 months.
Empty recipient paraffin blocks were prepared and 6 伊 7 holes of 2 mm diameter with a interval of 1 mm were made with tissue microarray instrument. All specimens were observed after conventional HE staining. One representative site of each specimen was selected and tissue cores of 2 mm diameter obtained by punching with tissue microarray instrument were placed into the corresponding holes of the empty recipient paraffin blocks. Two holes in the upper left corner with mouse tissues were used for location. All specimens were made into tissue microarrays. Paraffinembedded microarray blocks were cut into 4滋 m serial sections and the sections were placed on the glass slides treated with 1% polylysine. All microarray tissue sections were observed after HE staining.
The primary antibody of PAK1 protein was purchased from Wuhan Boster Biological Technology, Co., Ltd. and immunohistochemistry kits were purchased from Beijing Zhong Shan Golden Bridge Biotechnology Co., Ltd. Monoclonal rabbit antihuman PAK1 antibody was used at 1 颐 50 dilution and the secondary antibody was working solution of immunohistochemical kit without dilution. Immunohistochemical staining was performed according to the instructions provided by SP kit. Antigen retrieval was performed by boiling for 10 min in a microwave oven with 10 mmol/L sodium citrate buffer (pH 6.0). Positive controls were provided by the company and using PBS instead of the primary antibody as negative controls.
Immunohistochemical positive staining showed as yellow or/and brown granules located in cytoplasm or on cell membrane. The semiquantitative scoring method is as follows: according to the percent of positively stained cells, a percent of < 5% was defined as 0, 5% 25% as 1, 26% 50% as 2, and > 50% as 3; according to the staining intensity of positive cells, no staining was defined as 0, yellow as 1, brown as 2, and dark brown as 3. According to the sum of the two scores, the sections with a point more than or equal to 3 were positive and less than 3 were negative.
The statistical software SPSS 15.0 was used to analyze the data. The 2 test was used for statistic data. The KaplanMeier method was used for univariate analysis. Statistical significance was assumed when < 0.05. PAK1 protein was mainly expressed in cytoplasm, showing brown or dark brown stained granules (Figure 1) . The positive rate of PAK1 was significantly higher in gastric cancer than in adjacent tissues normal control (73.0% vs. 57.4% and 23.3% , 2 = 4.544 and 2 = 28.565, < 0.05). The difference between adjacent tissues and normal control was also significant ( 2 = 9.039, <0.05).
The expression of PAK1 in gastric cancer was closely related to tumor size, differentiation degree, lymph node metastasis, depth of invasion, and Lauren type, while not related to age and Borrman classification ( Table 1 ).
The positive rate of PAK1 was 52.5% in metastatic lymph nodes, significantly lower than that in primary gastric cancer ( 2 = 4.381, = 0.036).
KaplanMeier survival curves showed that the median survival time of 101 patients with followup was 28 months. The 3 and 5year overall survival rates of the whole group were 46.3% and 39.6% . The median survival was significantly shorter in PAK1positive patients than in PAK1negative patients (19 months vs. 78 months, 2 = 6.857, = 0.009) (Figure 2 ). Univariate survival analysis showed that PAK1 expression was a risk factor that affecting survival of patients.
PAK1 is expressed in the brain, muscles and spleen, and rarely in other tissues, but it is highly expressed in most human tumor cells, especially in breast and ovarian cancer cells. Studies have found that PAK1 protein is highly expressed in colorectal cancer [7] . The present study found that PAK1 was expressed in gastric cancer tissues, adjacent tissues and normal tissues. The positive rate of PAK1 was significantly higher in gastric cancer than in adjacent tissues and normal tissues, and higher in adjacent tissues than in normal tissues. Therefore, we speculated that PAK1 may be an early molecular event in gastric cancer and that its expression plays an important role in promoting the development and malignant transformation of gastric cancer.
Recent studies have shown that kinases play a pivotal role in the cellular signaling pathway and play a key regulatory role in signal transduction network of cancer. PAK1 can be activated by a variety of extracellular stimulating factors and participates in many important cellular activities such as cytoskeleton reorganization, evolution of the cell cycle, apoptosis and survival, regulation of gene transcription, invasion and metastasis of cancer cells, and so on. Our study found that the expression of PAK1 was closely associated with tumor size, PAK1, suggesting that the induction of tumor phenotype transformation by PAK1 may be related to its abnormalities of combination with specific substrates [7] . The extensive biological functions of PAK1 are caused by phosphorylating downstream target proteins after its activation, and it plays an important role in mitosis of normal cells while becomes dysfunctional in tumor cell nuclear receptormediated signaling pathways in breast cancer, prostate cancer, and so on, suggesting that PAK1 plays an important role in the development of normal tissues and the progression of tumor [8] . Studies have showed that PAK1 inhibited the function of zinc finger protein Snail in breast cancer cell lines by phosphorylating Snail protein to promote the transformation of cancer cells from epithelial celllike phenotype to mesenchymal celllike phenotype, a more invasive and poorly differentiated phenotype [ 9] . Schraml . [10] found that the increase of PAK1 copies was negatively correlated with the degree of differentiation of ovarian cancer. Xie .
[11] also confirmed that PAK1 protein was overexpressed in the vast majority of poorly differentiated ovarian cancers and its overexpression rate was significantly higher than that in welldifferentiated (G1G2) tumors.
The mechanisms of PAK1 in tumorigenesis, development, and metastasis of gastric cancer are unclear yet. Wu . [7] found that overexpression of PAK1 protein can promote the tumorigenesis and development of colorectal cancer and may be closely related to the malignant phenotype of colorectal cancer. We also found that PAK1 expression was closely associated with invasion and metastasis of gastric cancer, probably because that PAK1 was the first identified downstream effector molecule of RHOGTP enzyme RHO GTPases. With the mediation of growth factor, PAK1 can promote the cytoskeleton remodeling, thus contributing to cell migration and metastasis. Carter . [12] detected PAK1 expression in 38 specimens of colon cancer and found that PAK1 expression was positively correlated with stage and metastasis of colorectal cancer. Studies have confirmed that PAK1 is closely correlated with invasion and metastasis of breast cancer, ovarian cancer, and prostate cancer [5] . Its mechanism is that PAK1 mutants with the kinase catalytic activity can promote breast cancer cells to grow without support materials via the mitogenactivated protein kinase (MAPK) pathway [13] . In addition, the inhibition of protein kinase A (PKA) can promote nonanchored tumor cell growth through activation of growth factorPAKMAPK signaling cascade [14] . Therefore, we speculated that overexpression of PAK1 protein in gastric cancer could be used as a new indicator to evaluate the degree of malignancy of gastric cancer and may help to predict the invasion, metastasis, and prognosis of gastric cancer, which made it possible to be an effective drug target in the treatment of gastric cancer.
The present study found that the positive rate of PAK1 was lower in metastatic lymph nodes than in primary gastric cancer. That was considered to be associated with tumor heterogeneity. Although malignant tumors are formed by monoclonal proliferation of malignant transformed cells, daughter cells formed after many divisions may come up with different changes in genes or other macromolecules in the process of growth, and have diversities in many aspects, such as growth rate, invasion ability, and response to growth signals.
Using KaplanMeier curve to analyze the survival of 101 patients with followup, it was found that PAK1 expression was closely associated with survival and was a risk factor for survival. We found that there were significant differences of PAK1 expression in gastric cancer, adjacent tissues and normal tissues, which was an early molecular event in gastric cancer; PAK1 expression, closely related to lymph node metastasis, depth of invasion, and degree of differentiation, was a valuable indicator in evaluating the degree of malignancy in gastric cancer and thus would contribute to the predication of invasion and metastasis of gastric cancer; PAK1 expression was closely related to survival of patients and would help predicting the prognosis of patients. The possible mechanism of interaction between PAK1 and other genes in gastric cancer deserves further study.
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